NAFLD and NASH: etiology, targets and emerging therapies

Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)

Discovery of an insulin‐induced gene binding compound that ameliorates nonalcoholic steatohepatitis by inhibiting sterol regulatory element‐binding protein–mediated lipogenesis